SEARCH WITHIN CONTENT
VOLUME 25 , ISSUE 8 ( August, 2021 ) > List of Articles
Wiaam Y Elkhatib, Hollie Saunders, Scott A Helgeson, John E Moss
Keywords : Cardiopulmonary bypass, Chronic myelomonocytic leukemia, Coronary artery bypass grafting, Cytokine release syndrome, Systemic inflammatory response syndrome, Tocilizumab
Citation Information : Elkhatib WY, Saunders H, Helgeson SA, Moss JE. The Use of an Interleukin-6 Inhibitor in Vasoplegic Shock from Severe Systemic Inflammatory Response Syndrome: A Case Report. Indian J Crit Care Med 2021; 25 (8):939-941.
License: CC BY-NC 4.0
Published Online: 12-08-2021
Copyright Statement: Copyright © 2021; The Author(s).
A 66-year-old Caucasian male with a history of chronic myelomonocytic leukemia (CMML) developed fluid-unresponsive hypotension requiring initiation of four different maximum dosed vasopressors, steroids, and broad-spectrum antibiotics 4 hours following four-vessel coronary artery bypass grafting involving a 150-minute cardiac bypass. Placement of a Swanz-Ganz catheter showed a cardiac output of 7 L/minute with systemic vascular resistance of 571 dynes/sec/cm−5. Over 24 hours, three doses of tocilizumab (interleukin-6 inhibitor) every 8 hours were initiated, plus 250 mg methylprednisolone per 6 hours increment, and then daily thereafter. After the initial dose of tocilizumab, it was possible to wean vasoconstrictors. We have shown for the first time that therapy with tocilizumab is effective in reversing the hemodynamic instability associated with the significant systemic inflammatory response from the “double hit” of CMML and coronary artery bypass grafting with cardiopulmonary bypass as has previously been shown in cytokine release syndrome.
© Jaypee Brothers Medical Publishers (P) LTD.